<code id='848DECC899'></code><style id='848DECC899'></style>
    • <acronym id='848DECC899'></acronym>
      <center id='848DECC899'><center id='848DECC899'><tfoot id='848DECC899'></tfoot></center><abbr id='848DECC899'><dir id='848DECC899'><tfoot id='848DECC899'></tfoot><noframes id='848DECC899'>

    • <optgroup id='848DECC899'><strike id='848DECC899'><sup id='848DECC899'></sup></strike><code id='848DECC899'></code></optgroup>
        1. <b id='848DECC899'><label id='848DECC899'><select id='848DECC899'><dt id='848DECC899'><span id='848DECC899'></span></dt></select></label></b><u id='848DECC899'></u>
          <i id='848DECC899'><strike id='848DECC899'><tt id='848DECC899'><pre id='848DECC899'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:85
          Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference
          JUSTIN TALLIS/AFP via Getty Images

          LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

          At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

          advertisement

          In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more
          Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’
          Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

          PaulTonkoofNewYork:“Thispackagefallsfarshortoftakingthenecessarystepstoaddressthedeepneedofthiscrisi

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          House looks to weaken Medicare negotiation

          TheHouseofRepresentativesishavingahearingontwobillsthatcouldweakenMedicare'sdrugpricenegotiationproc